Alnylam Pharmaceuticals Inc

ALNY

Equity

ISIN US02043Q1076 / Valor 1806798

NASDAQ (2025-04-04)

USD 235.74-10.1%

Alnylam Pharmaceuticals Inc
UMushroom community rating:

3.00 1 votes No rating yet

NegativeNeutralPositive

About company

Alnylam Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing RNAi therapeutics for diseases with high unmet medical needs. Their robust pipeline includes investigational treatments for genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system and ocular diseases. With more than a dozen RNAi therapeutics in clinical development, including multiple in late-stage development, Alnylam is dedicated to advancing innovative treatments to address significant health challenges.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

55.6%1Y

45.7%3Y

123%5Y

Performance

48.4%1Y

49.4%3Y

47.7%5Y

Volatility

30694 M

Market cap (USD)

1,881,632

Daily traded volume (Shares)

236.59 / 233.29

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

3.00

1 votes

Performance:

3.00

Innovation:

4.00

Society:

4.00

Nature:

3.00

Andy S

Switzerland, 28 Mar 2025

Für das aktuelle Geschäftsjahr erwarten Analysten einen Zuwachs des Gewinns um 1.762,5%. Insgesamt spricht die unzuverlässige Gewinnentwicklung für ein unsicheres Investment mit erhöhtem Risiko.

EQUITIES OF THE SAME SECTOR

Quest Diagnostics Inc